The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis
Open accessAbstract
Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial (TMC207-C208;NCT00449644). The current phase 2, multicenter, open-label, single-arm trial (TMC207-C209;NCT00910871) reported here was conducted to confirm the safety and efficacy of bedaquiline. Newly diagnosed or previously treated patients with MDR-TB (including pre-extensively drug-resistant (pre-XDR)-TB or extensively drug-resistant (XDR)-TB) received bedaquiline for 24 weeks with a background regimen of anti-TB drugs continued according to National TB Programme treatment guidelines. Patients were assessed during and up to 120 weeks after starting bedaquiline. Of 233 enrolled patients, 63.5% had MDR-TB, 18.9% had pre-XDR-TB and 16.3% had XDR-TB, with 87.1% having taken second-line drugs prior to enrolment. 16 patients (6.9%) died. 20 patients (8.6%) discontinued before week 24, most commonly due to adverse events or MDR-TB-related events. Adverse events were generally those commonly associated with MDR-TB treatment. In the efficacy population (n=205), culture conversion (missing outcome classified as failure) was 72.2% at 120 weeks, and 73.1%, 70.5% and 62.2% in MDR-TB, pre-XDR-TB and XDR-TB patients, respectively. Addition of bedaquiline to a background regimen was well tolerated and led to good outcomes in this clinically relevant patient cohort with MDR-TB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global tuberculosis report (2014)
Gabbasova, L. A., & Who, E. R. E. (2014) · Cited by 12,702
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationThe Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
Self-citationTowards tuberculosis elimination: an action framework for low-incidence countries
Lönnroth, K., Migliori, G. B., Abubakar, I., D'Ambrosio, L., de Vries, G., Diel, R., Douglas, P., Falzon, D., Gaudreau, M.-A., Goletti, D., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00214014 · Cited by 778
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Diacon, A. H., Pym, A., Grobusch, M. P., de los Rios, J. M., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Marez, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313865 · Cited by 746
Self-citationShort, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Worldwide Emergence of Extensively Drug-resistant Tuberculosis
Shah, N. S., Wright, A., Bai, G.-H., Barrera, L., Boulahbal, F., Martín-Casabona, N., Drobniewski, F., Gilpin, C., Havelková, M., Lepe, R., et al. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1303.061400 · Cited by 583
Ahuja, S. D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J. N., Becerra, M. C., Benedetti, A., Burgos, M., Centis, R., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001300 · Cited by 535
Hartkoorn, R. C., Uplekar, S., & Cole, S. T. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00037-14 · Cited by 489
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Andries, K., Villellas, C., Coeck, N., Thys, K., Gevers, T., Vranckx, L., Lounis, N., de Jong, B. C., & Koul, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102135 · Cited by 439
Self-citation
Cited by
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901814 · Cited by 1,044
Self-citationDheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
Conradie, F., Bagdasaryan, T. R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., Samoilova, A., Skornykova, S., Tudor, E., Variava, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119430 · Cited by 578
Self-citationMiotto, P., Tessema, B., Tagliani, E., Chindelevitch, L., Starks, A. M., Emerson, C., Hanna, D., Kim, P. S., Liwski, R., Zignol, M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01354-2017 · Cited by 327
Lan, Z., Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., Brode, S. K., Brust, J. C. M., Campbell, J. R., Chang, V. W. L., Falzon, D., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30047-3 · Cited by 268
Wallis, R. S., Maeurer, M., Mwaba, P., Chakaya, J., Rustomjee, R., Migliori, G. B., Marais, B., Schito, M., Churchyard, G., Swaminathan, S., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00070-0 · Cited by 262
Metadata
- Authors
- Pym, A. S., Diacon, A. H., Tang, S.-J., Conradie, F., Danilovits, M., Chuchottaworn, C., Vasilyeva, I., Andries, K., Bakare, N., De Marez, T., Haxaire-Theeuwes, M., Lounis, N., Meyvisch, P., Van Baelen, B., van Heeswijk, R. P. G., & Dannemann, B.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2015-12-02
- Volume
- 47
- Issue
- 2
- Pages
- 564-574
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2262666571
- Cited by
- 333
- References
- 26
- FWCI
- 21.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.